Tag: Bright Minds Biosciences - Psychedelic Alpha

Join our weekly Bulletin for the latest updates and analysis.

Read more about the article Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Post published:September 8, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Post published:August 31, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Post published:August 31, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Comments on Recent Trading Activity

Bright Minds Biosciences Comments on Recent Trading Activity

Post published:August 18, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

Post published:June 27, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Post published:May 22, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Post published:May 2, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

Post published:March 14, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Post published:November 30, 2021
Post category:Press Release

Read more about the article Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Post published:November 3, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.